RecruitingPhase 3NCT04261244

NeoRad Breast Cancer Study

Preoperative Radiotherapy Versus Postoperative Radiotherapy After Neoadjuvant Chemotherapy ("NeoRad") in High-risk Breast Cancer: a Prospektiv, Randomized, International Multicenter Phase III Trial


Sponsor

Bielefeld University

Enrollment

1,826 participants

Start Date

Feb 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The NEORAD trial tests whether preoperative radiotherapy results in an improved DFS and less radiation induced late effect compared to postoperative radiotherapy in higher risk breast cancer after NACT.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria10

  • Histologically proven invasive, unilateral breast cancer
  • Indication for radiotherapy
  • Indication for neoadjuvant chemotherapy (+/- antibody treatment or other targeted therapies) in accordance with national and international guidelines
  • Female
  • Informed consent for the trial signed by the patient
  • Hormone receptor and HER2 status: no restrictions
  • All grades G1-G3
  • Age ≥ 18 years at the time of informed consent
  • Performance status ≤ 2
  • No pre-existing conditions that prohibit therapy

Exclusion Criteria15

  • Neoadjuvant treatment solely with endocrine therapy
  • Bilateral breast cancer
  • Pregnancy or lactation
  • Prior radiotherapy of the thorax
  • Connective tissue disease, including rheumatoid arthritis and thromboangiitis obliterans
  • Pre-existing symptomatic chronic lung disease (fibrosis, pneumoconiosis, adult-onset allergies, such as farmer's lung, severe lung emphysema, COPD °III)
  • Cardiac comorbidities: symptomatic coronary heart disease, prior heart attack, heart failure NYHA ≥II or AHA ≥C, pacemaker, and/or implanted defibrillator
  • Malignoma except basalioma or in-situ-carcinomas in complete response
  • Distant metastasis
  • Plexopathies of the arm of the treated side
  • Stiffness of the shoulder of the arm of the side of the breast cancer of any origin (e.g. following a road accident)
  • Lymph edema ≥°II of the arm at the side of the breast cancer
  • Other medical conditions that prohibit the neoadjuvant radiotherapy (i.e. Expected non-compliance, etc.)
  • Male patients
  • Patients who have previously been assessed for chemotherapy response

Interventions

RADIATIONpreoperative radiotherapy

preoperative radiotherapy instead of postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy

RADIATIONpostoperative radiotherapy

postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy


Locations(16)

St. Marien-Krankenhaus Ahaus

Ahaus, Germany

Hochtaunus-Kliniken

Bad Homburg, Germany

Sana Klinikum Lichtenberg

Berlin, Germany

St. Agnes-Hospital

Bocholt, Germany

Städtisches Klinikum Dessau

Dessau, Germany

Universitätsfrauenklinik UK OWL, Klinikum Lippe

Detmold, Germany

Universitätsklinikum Düsseldorf

Düsseldorf, Germany

Niels-Stensen-Kliniken Franziskus-Hospital Harderberg

Georgsmarienhütte, Germany

Sana Klinikum Hameln-Pyrmont

Hamelin, Germany

Sana Klinikum Offenbach

Offenbach, Germany

medius Klinik Ostfildern-Ruit

Ostfildern, Germany

Leopoldina Krankenhaus Schweinfurt

Schweinfurt, Germany

Johanniter-Krankenhaus Stendal

Stendal, Germany

Rems-Murr-Klinikum Winnenden

Winnenden, Germany

Helios Universitätsklinikum Wuppertal

Wuppertal, Germany

Heinrich-Braun-Klinikum

Zwickau, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04261244


Related Trials